PACAP Receptor

By Targets:	PACAP Receptor (12) Adenylate Cyclase (2) Amino Acid Derivatives (2) Calcium Channel (2) EGFR (2) ERK (2) Reactive Oxygen Species (ROS) (2)
By Research Areas:	Cancer (1) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (15)

Targets Recommended: PACAP Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-133529

PA-8 2 Publications Verification	PACAP Receptor	Neurological Disease Inflammation/Immunology
PA-8 is a potent, selective and orally active **PACAP type I (PAC1) receptor** antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC₅₀ of 2 nM .

HY-P99509

Zelminemab AMG-301	Adenylate Cyclase	Neurological Disease
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits **PACAP type I (PAC1) receptor** .

HY-P0176

PACAP (1-27), human, ovine, rat 3 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent *PACAP* receptor agonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Metabolic Disease
PACAP (1-38) free acid is a desamido-PACAP (1-38), human, ovine, rat (HY-P0221). PACAP (1-38) free acid can activate the human PAC1 receptor. PACAP (1-38) free acid induces cyclic AMP (cAMP) generation in both NS-1 neuroendocrine cells and non-neuroendocrine HEK293 cells .

HY-147557

PA-915 1 Publications Verification PAC1R antagonist 1	PACAP Receptor	Neurological Disease
PA-915 (PAC1R antagonist 1) is a potent and orally active antagonist of PAC1 receptor. PA-915 inhibits pituitary adenylate cyclase-activating polypeptide (PACAP)-induced CREB phosphorylation. PA-915 can inhibit PACAP- and nerve injury-induced allodynia. PA-915 can be used for the research of neuropathic pain .

HY-P0220A

PACAP (6-38), human, ovine, rat TFA 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat TFA is a potent **PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor*, PACAP* type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P0220

PACAP (6-38), human, ovine, rat 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat is a potent **PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor*, PACAP* type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P1845

PACAP-38 (31-38), human, mouse, rat	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat does not bind to the PACAP receptor .

HY-P0176A

PACAP (1-27), human, ovine, rat TFA 3 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent *PACAP* receptor agonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively .

HY-129421

PA-9	PACAP Receptor	Neurological Disease Inflammation/Immunology
PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC₅₀ of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain .

HY-P4127A

M65 TFA	PACAP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat TFA does not bind to the PACAP receptor .

HY-P3117

PACAP (6-27) (human, ovine, rat) Pituitary adenylate cyclase-activating peptide (6-27)	Adenylate Cyclase	Neurological Disease
PACAP (6-27) (human, ovine, rat) is a *PACAP* receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

Cat. No.	Product Name	Target	Research Area

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P0176

PACAP (1-27), human, ovine, rat 3 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent *PACAP* receptor agonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Metabolic Disease
PACAP (1-38) free acid is a desamido-PACAP (1-38), human, ovine, rat (HY-P0221). PACAP (1-38) free acid can activate the human PAC1 receptor. PACAP (1-38) free acid induces cyclic AMP (cAMP) generation in both NS-1 neuroendocrine cells and non-neuroendocrine HEK293 cells .

HY-P0220A

PACAP (6-38), human, ovine, rat TFA 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat TFA is a potent **PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor*, PACAP* type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P0220

PACAP (6-38), human, ovine, rat 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat is a potent **PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor*, PACAP* type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P1845

PACAP-38 (31-38), human, mouse, rat	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat does not bind to the PACAP receptor .

HY-P0176A

PACAP (1-27), human, ovine, rat TFA 3 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent *PACAP* receptor agonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively .

HY-P4127A

M65 TFA	PACAP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat TFA does not bind to the PACAP receptor .

HY-P4127

M65	Peptides	Neurological Disease
M65 is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P3117

PACAP (6-27) (human, ovine, rat) Pituitary adenylate cyclase-activating peptide (6-27)	Adenylate Cyclase	Neurological Disease
PACAP (6-27) (human, ovine, rat) is a *PACAP* receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99509

Zelminemab AMG-301	Adenylate Cyclase	Neurological Disease
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits **PACAP type I (PAC1) receptor** .

Species:	Human (3)
Tag:	Fc (3)
Source:	HEK293 (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P76128

	VIPR2 Protein, Human (HEK293, Fc) Vasoactive intestinal polypeptide Receptor 2; VIP-R-2; PACAP-R3; VPAC2; VIPR2	Human	HEK293
	VIPR2 protein, serving as a receptor for Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activating Peptide (PACAP-38 and -27), activates adenylyl cyclase and can also couple with phospholipase C. Its versatile signaling pathways emphasize its pivotal role in transducing signals from VIP and PACAP, participating in cellular processes regulated by cyclic AMP and phosphoinositide signaling cascades. VIPR2 Protein, Human (HEK293, Fc) is the recombinant human-derived VIPR2 protein, expressed by HEK293 , with C-mFc labeled tag.

HY-P77120A

	ADCYAP1R1 Protein, Human (HEK293, hFc) Pituitary adenylate cyclase-activating polypeptide type I Receptor; PACAP-R1; ADCYAP1R1	Human	HEK293
	The ADCYAP1R1 protein is a receptor for pituitary adenylate cyclase-activating polypeptide (PACAP) and recognizes PACAP-27 and PACAP-38. Through the G protein, this receptor activates adenylyl cyclase, initiating multiple downstream signaling pathways. ADCYAP1R1 Protein, Human (HEK293, hFc) is the recombinant human-derived ADCYAP1R1 protein, expressed by HEK293, with C-hFc labeled tag.

HY-P77120

	ADCYAP1R1 Protein, Human (HEK293, Fc, solution) Pituitary adenylate cyclase-activating polypeptide type I Receptor; PACAP-R1; ADCYAP1R1	Human	HEK293
	The ADCYAP1R1 protein is a receptor for pituitary adenylate cyclase-activating polypeptide (PACAP) and recognizes PACAP-27 and PACAP-38. Through the G protein, this receptor activates adenylyl cyclase, initiating multiple downstream signaling pathways. ADCYAP1R1 Protein, Human (HEK293, Fc, solution) is the recombinant human-derived ADCYAP1R1 protein, expressed by HEK293 , with C-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (1) Rabbit (4)
Reactivity:	Human (4) human (1)
Application:	IHC-P (4) IP (1) WB (1) ELISA (1)
Isotype:	IgG (4) IgG1 (1)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P89687

	PACAP Receptor Antibody (YA9031)	WB, IP, ELISA	human
	PACAP Receptor Antibody (YA9031) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PACAP Receptor.

HY-P81526

	VPAC2 Antibody (YA1271) VIP2R; VIPR2; Vasoactive intestinal polypeptide Receptor 2; VIP-R-2; Helodermin-preferring VIP Receptor; Pituitary adenylate cyclase-activating polypeptide type III Receptor (PACAP type III Receptor; PACAP-R-3; PACAP-R3); VPAC2	IHC-P	Human
	VPAC2 Antibody (YA1271) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VPAC2.

HY-P81526A

	VPAC2 Antibody (YA1271)(PBS only) VIP2R; VIPR2; Vasoactive intestinal polypeptide Receptor 2; VIP-R-2; Helodermin-preferring VIP Receptor; Pituitary adenylate cyclase-activating polypeptide type III Receptor (PACAP type III Receptor; PACAP-R-3; PACAP-R3); VPAC2	IHC-P	Human
	VPAC2 Antibody (YA1271) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VPAC2.

HY-P81524

	VIPR1 Antibody (YA1269) vasoactive inTinal peptide Receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2	IHC-P	Human
	VIPR1 Antibody (YA1269) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VIPR1.

HY-P81524A

	VIPR1 Antibody (YA1269)(PBS only) vasoactive inTinal peptide Receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2	IHC-P	Human
	VIPR1 Antibody (YA1269) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VIPR1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies